Kale Ruby

Title: Kale Ruby - Innovator in Pharmaceutical Formulations

Introduction

Kale Ruby is a notable inventor based in San Diego, CA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of amylin agonist peptides. With a total of 2 patents, his work focuses on improving the stability and efficacy of these formulations for medical use.

Latest Patents

Kale Ruby's latest patents include innovative formulations for amylin agonist peptides. The first patent describes a pharmaceutical formulation that comprises approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system. This formulation also includes a buffer to maintain a pH of approximately 3.0 to about 6.0, along with a carbohydrate or polyhydric alcohol tonicifier. The formulation is designed to maintain stability under both refrigerated and room temperature conditions. Additionally, it can be combined with insulin for administration to patients.

The second patent similarly focuses on amylin agonist pharmaceutical compositions containing insulin. It outlines a formulation that includes the same components as the first patent, ensuring stability and compatibility for patient administration. These advancements are crucial for enhancing the treatment options available for patients requiring insulin and amylin agonist therapies.

Career Highlights

Kale Ruby is currently associated with Amylin Pharmaceuticals, Inc., where he continues to innovate in the field of pharmaceutical formulations. His work has been instrumental in developing products that improve patient outcomes and streamline the administration of critical medications.

Collaborations

Kale has collaborated with notable colleagues such as James J L'Italien and Shankar Musunuri. These partnerships have contributed to the advancement of his research and the successful development of his patented formulations.

Conclusion

Kale Ruby's contributions to pharmaceutical formulations, particularly in the area of amylin agonist peptides, highlight his role as an influential inventor in the medical field. His innovative patents and ongoing work at Amylin Pharmaceuticals, Inc. continue to pave the way for improved therapeutic options for patients.